Free shipping on all orders over $ 500

CEP-32496

Cat. No. M2045

All AbMole products are for research use only, cannot be used for human consumption.

CEP-32496 Structure
Synonym:

RXDX-105; Agerafenib

Size Price Availability Quantity
5mg USD 90 In stock
10mg USD 139 In stock
25mg USD 260 In stock
50mg USD 420 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CEP-32496 is a novel RAF inhibitor with IC50 values of 14 nM, 36 nM, 39 nM, 3 nM and 9 nM for BRAF(V600E), BRAF(WT), c-Raf, Abl-1 and CSF-1R, respectively. CEP-32496 is orally bioavailable in multiple preclinical species (>95% in rats, dogs, and monkeys) and has single oral dose pharmacodynamic inhibition (10-55 mg/kg) of both pMEK and pERK in BRAF(V600E) colon carcinoma xenografts in nude mice. In vitro, CEP-32496 has multikinase binding activity at other cancer targets of interest; however, it exhibits selective cellular cytotoxicity for BRAF(V600E) versus wild-type cells. CEP-32496 exhibits high potency against several BRAF(V600E)-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAF(V600E) versus those containing wild-type BRAF. CEP-32496 also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAF(V600E)-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID.

Chemical Information
Molecular Weight 517.46
Formula C24H22F3N5O5
CAS Number 1188910-76-0
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] James J, et al. Mol Cancer Ther. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.

[2] Rowbottom MW, et al. J Med Chem. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

Related Raf Products
GDC-0879

GDC-0879 is a potent and selective B-Raf kinase inhibitor with an EC50 of 0.75 µM.

Vemurafenib (PLX4032)

Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy.

PLX-4720

PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively.

SB590885

SB590885 is a selective small-molecule inhibitor of the B-Raf kinase and Ki values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively.

ZM 336372

ZM 336372 is a potent, selective ATP-competitive inhibitor of c-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf).

  Catalog
Abmole Inhibitor Catalog




Keywords: CEP-32496, RXDX-105; Agerafenib supplier, Raf, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.